Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Video

What is acute myeloid leukemia? How is it different from myelodysplastic syndromes?

Posted by
HealthTree Logo HealthTree
• July 22, 2024

Description

Learn about acute myeloid leukemia and how it differs from myelodysplastic syndromes in this video.

On this video

Healthtree contact Jonathan Feld, Specialist

Jonathan Feld, Specialist

Mount Sinai Health System

Transcript

What is AML and how is it different from MDS?

AML is a more aggressive form of a high-risk MDS. In terms of explaining it, I tend to think of MDS as two different diseases. Patients with a lower-risk MDS have what we call a bone marrow failure state where their main issue is having a low red blood cell count, so anemia, or a low platelet count, thrombocytopenia, or a low white blood cell count, or neutropenia. In those cases, there is a low risk of transformation to acute myeloid leukemia and higher-risk MDS. That's almost like a pre-AML state. It still has the bone marrow failure portion of it where patients have low blood counts, but they also have a higher risk of transformation to AML.

Previously, and what we still think of now, is the cutoff between MDS and AML is 20% involvement of the bone marrow with blast or leukemia cells. Patients who have less than 20% are considered to have MDS, and patients with more than 20% are considered to have leukemia. However, in recent years, we've come to see that line can be blurred. And so sometimes now we consider 10 to 20% blast or bad cells to be leukemia.

Related Content